We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topics
- Shortages and supply disruptions (21)
- Safety monitoring and information (13)
- Manufacturing (7)
- Compliance and enforcement (6)
- Labelling and packaging (4)
- Import and export (3)
- Scheduling (national classification system) (3)
- Committees and advisory bodies (2)
- Legislation (2)
- Advertising (1)
- Clinical trials (1)
- Fees and payments (1)
- Medicinal cannabis hub (1)
Collection content
113 result(s) found, displaying 61 to 70
-
PageInformation on colourings in medicines for topical and oral use.
-
PageThe Scheduling Policy Framework (Scheduling Policy) sets out the national policy for applying access restrictions on medicines and chemicals.
-
PageFind out about our clinical evaluation streams and the functions each unit provides.
-
PageThis information explains your responsibilities when obtaining Good Manufacturing Practice (GMP) clearance by any pathway, or by GMP certification following our inspection.
-
PageA new version of the code of practice for tamper-evident packaging of therapeutic goods is now available
-
PageInformation for sponsors on demonstrating stability of medicines under Australian conditions.
-
PageWe provide transparency of the prescription medicines registration process via the online publication of Australian Public Assessment Reports (AusPARs). Explore questions and answers about AusPARs.
-
PageHow to submit nonclinical studies in Module 4 of the Common Technical Document (CTD).
-
GuidanceGuidance providing an overview of the Common Technical Document (CTD), modules 1-5. The CTD is a set of dossier specifications for the registration of medicines.
-
PageInformation on special considerations required for medicines for use in special populations.